A quantitative approach to drug dosing in chronic kidney disease

Blood Purification

Volumn 31, Issue 1-3, 2011, Pages 138-145

  Olyaei, Ali J ^a   Steffl, Jessica L ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Dialysis; Drug dosing; Drug pharmacokinetics

Indexed keywords

AMIODARONE; CANNABINOID; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; DANAZOL; DELAVIRDINE; DEXTROPROPOXYPHENE; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; FUROSEMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; MIBEFRADIL; MICONAZOLE; MIDAZOLAM; NEFAZODONE; NELFINAVIR; NORFLOXACIN; OMEPRAZOLE; PHENYTOIN; PHOSPHATE BINDING AGENT; TRIMETHOPRIM; UNINDEXED DRUG;

ADVERSE DRUG REACTION; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONFERENCE PAPER; DIALYSIS; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG TRANSFORMATION; GASTROINTESTINAL TRACT FUNCTION; HEALTH CARE PERSONNEL; HEART FUNCTION; HUMAN; KIDNEY FAILURE; LIVER FUNCTION; NEPHROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; RENAL REPLACEMENT THERAPY; TREATMENT FAILURE;

HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 78651428403     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321857     Document Type: Conference Paper

References (38)

1. Brater DC: Drug dosing in patients with impaired renal function. Clin Pharmacol Ther 2009; 86: 483-489.
2. Aymanns C, Keller F, Maus S, Hartmann B, Czock D: Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010; 5: 314-327.
3. Churchwell MD, Mueller BA: Drug dosing during continuous renal replacement therapy. Semin Dial 2009; 22: 185-188.
4. Vilay AM, Churchwell MD, Mueller BA: Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care 2008; 12: 235.
5. Olyaei AJ, Bennett WM: Drug dosing in the elderly patients with chronic kidney disease. Clin Geriatr Med 2009; 25: 459-527.
6. Macedo E, Bouchard J, Soroko SH, Chertow GM, Himmelfarb J, Ikizler TA, et al: Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. Crit Care 2010; 14:R82.
7. Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, et al: Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis 2003; 41: 386-393.
8. Manley HJ, Cannella CA, Bailie GR, St Peter WL: Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005; 46: 669-680.
9. Verbeeck RK, Musuamba FT: Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009; 65: 757-773.
10. Verbeeck RK: Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-1161.
11. Bellomo R, Prowle JR, Echeverri JE: Diuretic therapy in fluid-overloaded and heart failure patients. Contrib Nephrol 2010; 164: 153-163.
12. Dong K, Quan DJ: Appropriately assessing renal function for drug dosing. Nephrol Nurs J 2010; 37: 304-308.
13. Rifkin DE, Winkelmayer WC: Medication issues in older individuals with CKD. Adv Chronic Kidney Dis 2010; 17: 320-328.
14. Hassan Y, Al Ramahi R, Abd AN, Ghazali R: Drug use and dosing in chronic kidney disease. Ann Acad Med Singapore 2009; 38: 1095-1103.
15. Lacerda G, Krummel T, Sabourdy C, Ryvlin P, Hirsch E: Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67(suppl 4):S28-S33.
16. Nolin TD: Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens 2008; 17: 555-559.
17. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong JM, et al: Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 2009; 85: 305-311.
18. Davison SN, Mayo PR: Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3- glucuronide in hemodialysis patients. J Opioid Manag 2008; 4: 335-344.
19. Spina SP, Ensom MH: Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 2007; 27: 389-398.
20. Guengerich FP, Rendic S: Update information on drug metabolism systems - 2009, part I. Curr Drug Metab 2010; 11: 1-3.
21. Rendic S, Guengerich FP: Update information on drug metabolism systems - 2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010; 11: 4-84.
22. Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69: 1777-1798.
23. Boobis A, Watelet JB, Whomsley R, Benedetti MS, Demoly P, Tipton K: Drug interactions. Drug Metab Rev 2009; 41: 486-527.
24. Wang J: CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Rev Mol Diagn 2009; 9: 383-390.
25. Narva AS: Assessment of kidney function for drug dosing. Clin Chem 2009; 55: 1609-1611.
26. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
27. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al: Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72: 247-259.
28. Stevens LA, Levey AS: Use of the MDRD study equation to estimate kidney function for drug dosing. Clin Pharmacol Ther 2009; 86: 465-467.
29. Spruill WJ, Wade WE, Cobb HH III: Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function. Clin Pharmacol Ther 2009; 86: 468-470.
30. Tidman M, Sjostrom P, Jones I: A Comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two. Nephrol Dial Transplant 2008; 23: 154-160.
31. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
32. Dowling TC, Matzke GR, Murphy JE, Burckart GJ: Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacotherapy 2010; 30: 776-786.
33. Goetz MB, Sayers J: Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-334.
34. Schetz M: Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care 2007; 13: 645-651.
35. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37: 2268-2282.
36. Bourquin V, Ponte B, Saudan P, Martin PY: Drugs dosing in intensive care unit during continuous renal replacement therapy (in French). Nephrol Ther 2009; 5: 533-541.
37. Gilmartin C: Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits. Am J Health Syst Pharm 2007; 64(suppl 8):S15-S22.
38. Decker BS, Mueller BA, Sowinski KM: Drug dosing considerations in alternative hemodialysis. Adv Chronic Kidney Dis 2007; 14:e17-e26.